Ki67 Index in Breast Cancer: Correlation with Other Prognostic Markers and Potential in Pakistani Patients

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 7, 2013, Pages 4353-4358

  Haroon, Saroona ^a   Hashmi, Atif Ali ^b   Khurshid, Amna ^b   Kanpurwala, Muhammad Adnan ^c   Mujtuba, Shafaq ^b   Malik, Babar ^d   Faridi, Naveen ^b  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^b CIVIL HOSPITAL   (Pakistan)

^c Mohammad Bin Qasim Medical and Dental College   (Pakistan)

^d SINDH INSTITUTE OF UROLOGY AND TRANSPLANTATION   (Pakistan)

Author keywords

Breast cancer; ER; HER2neu; Ki67 index; PR

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER STAGING; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84885458786     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.7.4353     Document Type: Article

References (41)

1. Aleskandarany MA, Rakha EA, Macmillan RD, et al (2010). MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups. Breast Cancer Res Treat, 127, 591-9.
2. Awadelkarim KD, Costantini RM, Osman I, Barberis MC (2012). Ki-67 Labeling Index in Primary Invasive Breast Cancer from Sudanese Patients: A Pilot Study. ISRN Pathology.
3. Billgren AM, Tani E, Liedberg A, Skoog L, Rutqvist LE (2002). Prognostic signifificance of tumor cell proliferation analyzed in fifine needle aspirates from primary breast cancer. Breast Cancer Res Treat, 71, 161-70.
4. Bonnefoi H, Underhill C, Iggo R, Cameron D (2009). Predictive signatures for chemotherapy sensitivity in breast cancer: are they ready for use in the clinic? Eur J Cancer, 45, 1733-43.
5. Bottini A (2005). Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial. Endocr Relat Cancer, 12, 383-92.
6. Collins LC, Botero ML, Schnitt SJ (2005). Bimodal frequency distribution of Estrogen Receptor immunohistochemical staining results in breast cancer. Am J Clin Pathol, 123, 16-20.
7. Colozza M, Azambuja E, Cardoso F et al (2005). Proliferative markers as prognostic and predictive tools in early breast cancer :where are we now? Ann Oncol, 16, 1723-27.
8. Cuzick J, Dowsett M, Wale C, et al (2009). Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and the comparison with the GHI recurrence score-results from TransATAC. Cancer Res, 69, 503.
9. Dai H, vant Veer L, Lamb J, et al (2005). A cell proliferation signature is a marker ofextremely poor outcome in a subpopulation of breast cancer patients. Cancer Res, 65, 4059-66.
10. Desmedt C, Sotiriou C (2006). Proliferation: the most prominent predictor of clinical outcome in breast cancer. Cell Cycle, 5, 2198-202.
11. Dowsett M (2006). Proliferation and apoptosis as markers of benefifit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res, 12, 1024-30.
12. Dowsett M, Procter M, McCaskill-Stevens W, et al (2009). Disease-free survival according to degree of HER2 amplifification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA trial. J Clin Oncol, 27, 2962-69.
13. Ellis LM, Fidler IJ (1996). Angiogenesis and metastasis. Eur J Cancer, 32, 2451-60.
14. Eppenberger U, Kueng W, Schlaeppi JM, et al (1998). Markers of tumor angiogenesis and proteolysis independently defifine high- and low-risk subsets of node-negative breast cancer patients. J Clin Oncol, 16, 3129-36.
15. Fasching PA, Heusinger K, Haeberle L, et al (2011). Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 11, 486.
16. Ferguson NL, Bell J, Heidel R, et al (2013). Prognostic value of breast cancer subtypes, ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in caucasian women. Breast J, 19, 22-30.
17. Gerdes J, Lemke H, Baisch H, et al (1984). Cell cycle analysis of a cell proliferation-associated human nuclear antigen defifined by the monoclonal antibody Ki-67. J Immunol. 133, 1710-5.
18. Gerdes J, Schwab U, Lemke H, Stein H (1983). Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer, 31, 13-20.
19. Gerdes J, Li L, Schlueter C, et al (1991). Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defifined by monoclonal antibody Ki-67. Am J Pathol, 138, 867-73.
20. Goldhirsch A, Ingle JN, Gelber RD, et al (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20, 1319-29.
21. Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol, 22,1736-47.
22. Haerslev T, Jacobsen GK, Zedeler K (1996). Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry withhistopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat, 37, 101-13.
23. Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70.
24. Harris L, Fritsche H, Mennel R, et al (2007). American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol, 25, 5287-312.
25. Keshgegian AA, Cnaan A (1995). Proliferation markers in breast carcinoma. Mitotic fifigure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol. 104, 42-9.
26. Learn PA, Yeh IT, McNutt M, et al (2005). HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. Cancer, 103, 2252-60.
27. Luporsi E, André F, Spyratos F, et al (2012). Ki-67: level of evidence and methodological considerations forits role inthe clinical management of breastcancer: analytical and critical review. Breast Cancer Res Treat, 132, 895-915.
28. Matsubara N, Mukai H, Fujii S, Wada N (2013). Different prognostic signifificance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer. Breast Cancer Res Treat, 137, 203-12.
29. Molino A, Micciolo R, Turazza M, et al (1997). Ki-67 immunostaining in 322primary breast cancers: associations with clinical and pathological variablesand prognosis. Int J Cancer, 74, 433-7.
30. Railo M, Luldin J, Haglund C, von Smitten K, Nordling S (2007). Ki-67, ER receptors, ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer. Tumour Biol, 28, 45-51.
31. Reyal F, Hajage D, Savignoni A, et al (2013). Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS One, 8, 55901.
32. Royston P, Altman DG, Sauerbrei W (2006). Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med, 25, 127-41.
33. Sahin AA, Ro J, Ro JY, et al (1991). Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Signifificant correlation with prognosis. Cancer, 68, 549-7.
34. Sharifi SN, Sadeghian F, Homaei SF,Haghighi F (2006). Immunohistochemical study of cell proliferation marker (ki-67), estrogen, and progesterone receptors expression in breast carcinoma. J Birjand Uni Med Sci, 3, 38-44.
35. Smith IE, Dowsett M, Ebbs SR, et al (2005). Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol, 23, 5108-16.
36. Strand C, Bak M, Borgquist S, et al (2013). The combination of Ki67, histological grade and estrogen receptor status identififies a low-risk group among 1,854 chemo-naive women with N0/N1 primary breast cancer. Springerplus, 2, 111
37. Trihia H, Murray S, Price K, et al (2003). Ki-67 expression in breast cancer, its association with grading systems, clinical parameters and other prognostic factors e a surrogate marker? Cancer, 97, 1321-31.
38. Van Diest PJ, van der Wall E, Baak JP (2004). Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol, 57, 675-81.
39. Viale G, Regan MM, Mastropasqua MG, et al (2008). Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst, 100, 207-12.
40. Whitfield ML, George LK, Grant GD et al (2006). Common markers of proliferation. Nat Rev Cancer, 6, 99-106
41. Wolff AC, Hammond ME, Schwartz JN, et al (2007). American society of clinical oncology/college of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 25, 118-45.